University of Colorado Cancer Center researchers have developed a first-of-its-kind drug combination that targets two cancer survival pathways, offering new hope for ovarian cancer patients with PARP inhibitor resistance.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045